Dimitar T Nikolov

7960513, Jun 14, 2011

Dec 19, 2005

11/721949

Martin Lackmann - Clayton, AU
Peter W. Janes - Clayton, AU
Dimitar B. Nikolov - New York NY, US
Nayanendu Saha - Calcutta, IN

Monash University - Clayton, Victoria
Memorial Sloan Kettering Cancer Center - New York NY

C07K 16/40

5303871, 530350, 5303881, 53038826

Elucidation of the crystal structure of an ADAM10 substrate-recognition and proteinase-positioning module comprising the protein cysteine-rich and disintegrin domains, and detailed functional analysis revealed that an acidic pocket within the cysteine-rich domain forms a substrate-recognition site. The binding of this pocket to receptor/ligand complexes facilitates effective ligand cleavage, which is prevented when critical residues within the pocket are changed. This provides use of the surface pocket within the extracellular domain of ADAM10, and the corresponding structure in related proteases such as ADAM17, as a target for structure-based computational and high-throughput screens for small-molecule substrate-specific inhibitors or monoclonal antibodies that inhibit ADAM protease cleavage of ephrins and other ADAM10 or ADAM17 substrates. These inhibitors will be useful in therapeutic intervention of tumour development, invasion and metastasis and other diseases which involve the activity of the ADAM10 and ADAM17 proteases, such as inflammation, cardio-vascular disease, arthritis and other auto-immune diseases.

20140065166, Mar 6, 2014

Apr 9, 2013

14/114465

Christopher C. Broder - Silver Spring MD, US
Deborah L. Fusco - Silver Spring MD, US
Kai Hu - New York NY, US
Dimitar B. Nikolov - New York NY, US

The Henry M. Jackson Foundation for the Advancemen t of Military Medicine, Inc. - Bethesda MD

C07K 16/10

4241591, 5303894, 536 2353, 4353201, 435339, 435 696

The invention described herein provides novel peptides. The novel peptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Nipah virus and/or Hendra virus.

20170008976, Jan 12, 2017

Feb 4, 2015

15/116487

- Clayton, Victoria, AU
- New York NY, US
Andrew M. SCOTT - Kew East, Victoria, AU
Dimitar B. NIKOLOV - New York NY, US
Nayanendu SAHA - Jackson Heights NY, US

C07K 16/40
G01N 33/574
C07K 16/30

Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.